Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine.
Walter NM, Wentsch HK, Bührmann M, Bauer SM, Döring E, Mayer-Wrangowski S, Sievers-Engler A, Willemsen-Seegers N, Zaman G, Buijsman R, Lämmerhofer M, Rauh D, Laufer SA. Walter NM, et al. Among authors: mayer wrangowski s. J Med Chem. 2017 Oct 12;60(19):8027-8054. doi: 10.1021/acs.jmedchem.7b00745. Epub 2017 Sep 7. J Med Chem. 2017. PMID: 28834431
Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine.
Wentsch HK, Walter NM, Bührmann M, Mayer-Wrangowski S, Rauh D, Zaman GJR, Willemsen-Seegers N, Buijsman RC, Henning M, Dauch D, Zender L, Laufer S. Wentsch HK, et al. Among authors: mayer wrangowski s. Angew Chem Int Ed Engl. 2017 May 2;56(19):5363-5367. doi: 10.1002/anie.201701185. Epub 2017 Apr 11. Angew Chem Int Ed Engl. 2017. PMID: 28397331
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
Engel J, Richters A, Getlik M, Tomassi S, Keul M, Termathe M, Lategahn J, Becker C, Mayer-Wrangowski S, Grütter C, Uhlenbrock N, Krüll J, Schaumann N, Eppmann S, Kibies P, Hoffgaard F, Heil J, Menninger S, Ortiz-Cuaran S, Heuckmann JM, Tinnefeld V, Zahedi RP, Sos ML, Schultz-Fademrecht C, Thomas RK, Kast SM, Rauh D. Engel J, et al. Among authors: mayer wrangowski s. J Med Chem. 2015 Sep 10;58(17):6844-63. doi: 10.1021/acs.jmedchem.5b01082. Epub 2015 Aug 31. J Med Chem. 2015. PMID: 26275028
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.
Ermann J, Matmusaev M, Haley EK, Braun C, Jost F, Mayer-Wrangowski S, Hsiao P, Ting N, Li L, Terenzio D, Chime J, Lukas S, Patnaude L, Panzenbeck M, Csordas D, Zheng J, Mierz D, Simpson T, King FJ, Klimowicz AP, Mbow ML, Fine JS, Miller CA, Fogal SE, Byrne FR. Ermann J, et al. Among authors: mayer wrangowski s. Am J Physiol Gastrointest Liver Physiol. 2021 Nov 1;321(5):G500-G512. doi: 10.1152/ajpgi.00163.2021. Epub 2021 Sep 8. Am J Physiol Gastrointest Liver Physiol. 2021. PMID: 34494462 Free article.
Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions.
Münster A, Sommer S, Kúkeľová D, Sigrist H, Koros E, Deiana S, Klinder K, Baader-Pagler T, Mayer-Wrangowski S, Ferger B, Bretschneider T, Pryce CR, Hauber W, von Heimendahl M. Münster A, et al. Among authors: mayer wrangowski s. Neuropharmacology. 2022 Aug 1;213:109078. doi: 10.1016/j.neuropharm.2022.109078. Epub 2022 May 10. Neuropharmacology. 2022. PMID: 35561791 Free article.